NCI Funding for HIV and AIDS Malignancies Research
Current NCI Funding Opportunities in HIV/AIDS and AIDS Malignancies are listed below.
Notice of Special Interest (NOSI): Use of Biological "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers
The purpose of this Notice of Special Interest (NOSI) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals. Research efforts that identify specific contributions of HIV infection and its potential interaction with other pathogens towards the development and pathogenesis of these cancers and provide information on the clinical outcomes of such cancers in the HIV-infected population are sought. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.
High or medium priority AIDS research as described in NOT-OD-15-137 is encouraged in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.
HIV/AIDS and the Tumor Niche
The purpose of this Funding Opportunity Announcement (FOA) is to advance our understanding of the role of the tumor niche or microenvironment in the risks, development, progression, and diagnosis of cancer observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS). For this purpose, the National Cancer Institute (NCI) will support several U54 Specialized Centers.
The tumor niche for the purposes of this FOA is focused on an ecological niche, which in this case are the specific host environmental/microenvironmental conditions as the result of an underlying HIV infection that could be encountered by the host and establish an environment for tumor initiation and progression.
Additional Information: HIV/AIDS and the Tumor Niche (U54 Clinical Trial Not Allowed)
U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers
The purpose of this Funding Opportunity Announcement (FOA) is to support research on human immunodeficiency virus (HIV)-associated cancers in low- and middle-income countries (LMICs) through the formation of collaborative partnerships between investigators in United States (U.S.) and investigators in LMICs. These partnerships are referred to as HIV-Associated Malignancy Research Centers (HAMRCs).
Each proposed U54 HAMRC should be based upon partnerships involving at least one U.S. institution and institutions from at least two or more LMICs. Each HAMRC application is required to propose between two to three research projects that address questions in one scientific theme (e.g. viral-associated cancers) that is relevant to HIV-associated malignancies in LMICs or the U.S.
Additional Information: U.S. and Low- and Middle-Income HIV-Associated Malignancy Research Centers (U54 Clinical Trials Optional)
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions
The goal of this Funding Opportunity Announcement (FOA) is to support locally relevant research in critical areas of HIV-associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) Institutions, to enhance research capacity and build a network of researchers both within and across LMICs to address this critical burden. This initiative is expected to stimulate new research on the interplay between HIV and development of NCDs including cancer in persons living with HIV (PLWH).
Additional Information: HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
Provocative Questions (PQs) in Cancer with an Underlying HIV Infection
The purpose of this Funding Opportunity Announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS). These Provocative Questions are meant to challenge researchers to think about and elucidate specific problems and paradoxes in key areas of AIDS-related cancer research that are deemed important but have not received sufficient attention.Additional Information:
Multidisciplinary Studies of HIV/AIDS and Aging
This initiative solicits applications at the intersection of HIV and aging. NCI is interested in studies that help to understand how aging in the presence of chronic HIV infections affects risk, spectrum and biology of cancer.Additional Information:
Harnessing Big Data to Halt HIV
This funding opportunity announcement (FOA) encourages applications that will transform understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). NIH is interested in promoting and applying Big Data Science technologies, computing, informatics, and analytics to address gaps in our understanding of HIV transmission risks, social networks, and the HIV treatment continuum including comorbidities such as cancer.
Additional Information: Harnessing Big Data to Halt HIV (R01)
Tobacco Use and HIV in Low and Middle Income Countries
This initiative encourages research focused on tobacco use and HIV in low and middle income countries. In particular, applications focused on the development and evaluation of tobacco cessation interventions targeted to HIV positive persons with co-morbidities such as tuberculosis.
Additional Information: Tobacco Use and HIV in Low and Middle Income Countries (R01)
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle Income Countries
NCI is interested in encouraging applications that propose evidence based studies to reduce cancer stigma among healthcare providers, caregivers and cancer patients living with HIV/AIDS.